American Obesity Association website. Available at:
Arterburn DE, Crane PK, Veenstra DI. The efficacy and safety of sibutramine for weight loss: a systematic review.
Arch Intern Med.
Facts and comparisons.
Drug Facts and Comparisons. 56th ed. St. Louis, MO: Facts and Comparisons; 2001.
Haddock CK, Poston WSW, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.
Int J Obes Relat Meta Disord.
Li Z, Maglione M, Mojica W, Arterburn D, et al. Meta-analysis: Pharmacologic treatment of obesity.
Ann Intern Med.
The Merck Manual of Diagnosis and Therapy. 17th ed. Merck & Co; 1999.
Snow V, Barry P, Fitteman N, Qaseem A, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guidelines from the American College of Physicians.
Ann Intern Med.
Weight loss medications for obesity in adults. EBSCO DynaMed website. Available at:
. Updated August 8, 2011. Accessed September 23, 2011.
Wirth A, Krause J. Long-term weight loss with sibutramine: A randomized controlled trial.
11/20/2009 DynaMed's Systematic Literature Surveillance
: Pai You Guo, marketed as dietary supplement—recall. US Food and Drug Administration website. Available at:
. Published November 13, 2009. Accessed November 20, 2009.
1/22/2010 DynaMed's Systematic Literature Surveillance
: Meridia (sibutramine hydrochloride): follow-up to an early communication about an ongoing safety review. US Food and Drug Administration website. Available at:
. Published January 21, 2010. Accessed January 22, 2010.
5/28/2010 DynaMed's Systematic Literature Surveillance
: Orlistat (marketed as Alli and Xenical): labeling change. US Food and Drug Administration website. Available at:
. Published March 26, 2010. Accessed March 28, 2010.
9/17/2010 DynaMed's Systematic Literature Surveillance
: James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
N Engl J Med.
DynaMed's Systematic Literature Surveillance
: US Food and Drug Administration. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. US Food and Drug Administration website. Available at:
. Published October 8, 2010. Accessed October 15, 2010.
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.